Radiation-induced bystander signalling in cancer therapy

Por Prise, Kevin M., O'Sullivan, Joe M.
Publicado em 2009

Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy

Por Nugent, Brenda, Lewis, Sian, O'Sullivan, Joe M
Publicado no Cochrane Database Syst Rev (2013)

What is the Role of the Bystander Response in Radionuclide Therapies?

Por Brady, Darren, O’Sullivan, Joe M., Prise, Kevin M.
Publicado em 2013

Opportunities for research in molecular radiotherapy

Por Flux, Glenn D, O'Sullivan, Joe, Gaze, Mark N, Prise, Kevin M
Publicado no Br J Radiol (2017)

An exploration of men’s experiences of undergoing active surveillance for favourable-risk prostate cancer: A mixed methods study protocol

Por Ruane-McAteer, Eimear, O’Sullivan, Joe, Porter, Sam, Venderbos, Lionne, Prue, Gillian
Publicado no BMC Cancer (2016)

Fiducial marker guided prostate radiotherapy: a review

Por O'Neill, Angela G M, Jain, Suneil, Hounsell, Alan R, O'Sullivan, Joe M
Publicado no Br J Radiol (2016)

A study of the biological effects of modulated 6 MV radiation fields

Por Butterworth, Karl T, McGarry, Conor K, O’Sullivan, Joe M, Hounsell, Alan R, Prise, Kevin M
Publicado em 2010

A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy

Por Haseen, Farhana, Murray, Liam J, O'Neill, Roisin F, O'Sullivan, Joe M, Cantwell, Marie M
Publicado em 2010

OUT-OF-FIELD CELL SURVIVAL FOLLOWING EXPOSURE TO INTENSITY-MODULATED RADIATION FIELDS

Por Butterworth, Karl T., McGarry, Conor K., Trainor, Colman, O'Sullivan, Joe M., Hounsell, Alan R., Prise, Kevin M.
Publicado em 2011

Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT)

Por Brown, Malcolm, Murphy, Marie, McDermott, Lauri, McAneney, Helen, O’Sullivan, Joe M., Jain, Suneil, Prue, Gillian
Publicado no Pilot Feasibility Stud (2019)

The risk of cardiovascular disease in prostate cancer patients receiving androgen deprivation therapies.

Por Cardwell, Chris R., O’Sullivan, Joe M., Jain, Suneil, Harbinson, Mark T., Cook, Michael B., Hicks, Blánaid M., Menamin, Úna C. Mc
Publicado no Epidemiology (2020)

DNA Damage Responses following Exposure to Modulated Radiation Fields

Por Trainor, Colman, Butterworth, Karl T., McGarry, Conor K., McMahon, Stephen J., O’Sullivan, Joe M., Hounsell, Alan R., Prise, Kevin M.
Publicado em 2012

The mediastinal staging accuracy of 18F-Fluorodeoxyglycose Positron Emission Tomography / Computed Tomography in non-small cell lung cancer with variable time intervals to surgery.

Por Booth, Karen, Hanna, Gerard G, McGonigle, Niall, McManus, Kieran G, McGuigan, James, O’Sullivan, Joe, Lynch, Tom, McAleese, Jonathan
Publicado em 2013

A Kinetic-Based Model of Radiation-Induced Intercellular Signalling

Por McMahon, Stephen J., Butterworth, Karl T., Trainor, Colman, McGarry, Conor K., O’Sullivan, Joe M., Schettino, Giuseppe, Hounsell, Alan R., Prise, Kevin M.
Publicado em 2013

ELEVATION OF C-FLIP IN CASTRATE-RESISTANT PROSTATE CANCER ANTAGONIZES THERAPEUTIC RESPONSE TO ANDROGEN-RECEPTOR TARGETED THERAPY

Por McCourt, Clare, Maxwell, Pamela, Mazzucchelli, Roberta, Montironi, Rodolfo, Scarpelli, Marina, Salto-Tellez, Manuel, O’Sullivan, Joe M., Longley, Daniel B., Waugh, David J.J.
Publicado em 2012

Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy

Por Denis-Bacelar, Ana M, Chittenden, Sarah J, McCready, V Ralph, Divoli, Antigoni, Dearnaley, David P, O’Sullivan, Joe M, Johnson, Bernadette, Flux, Glenn D
Publicado no Br J Radiol (2018)

A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy

Por Lyons, Ciara A., King, Raymond B., Osman, Sarah O.S., McMahon, Stephen J., O’Sullivan, Joe M., Hounsell, Alan R., Jain, Suneil, McGarry, Conor K.
Publicado no Radiat Oncol (2017)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Por Heidenreich, Axel, Gillessen, Silke, Heinrich, Daniel, Keizman, Daniel, O’Sullivan, Joe M., Carles, Joan, Wirth, Manfred, Miller, Kurt, Reeves, John, Seger, Monica, Nilsson, Sten, Saad, Fred
Publicado no BMC Cancer (2019)

Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis

Por McCourt, Clare M., McArt, Darragh G., Mills, Ken, Catherwood, Mark A., Maxwell, Perry, Waugh, David J., Hamilton, Peter, O'Sullivan, Joe M., Salto-Tellez, Manuel
Publicado em 2013

Phase I/II trials of (186)Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival

Por Denis-Bacelar, Ana M., Chittenden, Sarah J., Dearnaley, David P., Divoli, Antigoni, O’Sullivan, Joe M., McCready, V. Ralph, Johnson, Bernadette, Du, Yong, Flux, Glenn D.
Publicado no Eur J Nucl Med Mol Imaging (2016)